BMO Capital Markets reaffirmed their outperform rating on shares of Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) in a report published on Wednesday. BMO Capital Markets currently has a $13.00 price target on the biopharmaceutical company’s stock, up from their prior price target of $12.00.

A number of other research analysts have also issued reports on TTPH. Stifel Nicolaus upgraded shares of Tetraphase Pharmaceuticals from a hold rating to a buy rating and boosted their price target for the stock from $8.00 to $15.00 in a research note on Wednesday. Zacks Investment Research lowered shares of Tetraphase Pharmaceuticals from a hold rating to a sell rating in a research note on Wednesday, May 10th. Finally, HC Wainwright began coverage on shares of Tetraphase Pharmaceuticals in a research note on Tuesday, July 11th. They set a buy rating and a $15.00 price target on the stock. Three equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. The company has an average rating of Buy and an average price target of $10.25.

Shares of Tetraphase Pharmaceuticals (TTPH) opened at 6.48 on Wednesday. The firm’s market capitalization is $245.95 million. Tetraphase Pharmaceuticals has a 12 month low of $3.11 and a 12 month high of $9.93. The firm’s 50-day moving average price is $7.45 and its 200 day moving average price is $6.85.

Tetraphase Pharmaceuticals (NASDAQ:TTPH) last posted its quarterly earnings data on Tuesday, May 2nd. The biopharmaceutical company reported ($0.79) EPS for the quarter, missing analysts’ consensus estimates of ($0.60) by $0.19. The business had revenue of $1.48 million during the quarter, compared to analyst estimates of $1.46 million. Tetraphase Pharmaceuticals had a negative net margin of 1,932.24% and a negative return on equity of 60.55%. The company’s revenue for the quarter was down 24.5% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.46) earnings per share. Analysts anticipate that Tetraphase Pharmaceuticals will post ($2.65) earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: “BMO Capital Markets Reiterates Outperform Rating for Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH)” was reported by Watch List News and is the sole property of of Watch List News. If you are viewing this report on another site, it was illegally copied and republished in violation of US and international copyright and trademark legislation. The correct version of this report can be viewed at https://www.watchlistnews.com/bmo-capital-markets-reiterates-outperform-rating-for-tetraphase-pharmaceuticals-inc-nasdaqttph/1462796.html.

Hedge funds have recently made changes to their positions in the stock. Wade G W & Inc. acquired a new stake in shares of Tetraphase Pharmaceuticals during the first quarter valued at about $138,000. Teza Capital Management LLC increased its stake in shares of Tetraphase Pharmaceuticals by 8.9% in the first quarter. Teza Capital Management LLC now owns 15,650 shares of the biopharmaceutical company’s stock valued at $144,000 after buying an additional 1,281 shares during the period. Citadel Advisors LLC increased its stake in shares of Tetraphase Pharmaceuticals by 18.6% in the first quarter. Citadel Advisors LLC now owns 15,924 shares of the biopharmaceutical company’s stock valued at $146,000 after buying an additional 2,496 shares during the period. UBS Group AG increased its stake in shares of Tetraphase Pharmaceuticals by 2.3% in the first quarter. UBS Group AG now owns 17,269 shares of the biopharmaceutical company’s stock valued at $159,000 after buying an additional 387 shares during the period. Finally, Jane Street Group LLC acquired a new stake in shares of Tetraphase Pharmaceuticals during the first quarter valued at about $181,000. 46.24% of the stock is currently owned by institutional investors.

Tetraphase Pharmaceuticals Company Profile

Tetraphase Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company uses its chemistry technology to create antibiotics for multidrug-resistant infections. The Company is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections, including multidrug-resistant gram-negative infections.

Analyst Recommendations for Tetraphase Pharmaceuticals (NASDAQ:TTPH)

Receive News & Ratings for Tetraphase Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetraphase Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.